Business Description
ImmuCell Corp
NAICS : 325412
SIC : 2834
ISIN : US4525253062
Total Employee Number:
73Description
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.53 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.44 | |||||
Debt-to-EBITDA | 5.14 | |||||
Interest Coverage | 5.82 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.91 | |||||
Beneish M-Score | -3.08 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.5 | |||||
3-Year EBITDA Growth Rate | 74 | |||||
3-Year Book Growth Rate | -8.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.14 | |||||
9-Day RSI | 52.38 | |||||
14-Day RSI | 54.56 | |||||
3-1 Month Momentum % | 25.39 | |||||
6-1 Month Momentum % | 43.52 | |||||
12-1 Month Momentum % | 52.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.82 | |||||
Quick Ratio | 2.6 | |||||
Cash Ratio | 1.74 | |||||
Days Inventory | 184.32 | |||||
Days Sales Outstanding | 35.1 | |||||
Days Payable | 21.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.3 | |||||
Shareholder Yield % | 1.41 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 42.59 | |||||
Operating Margin % | 8.36 | |||||
Net Margin % | -1.82 | |||||
EBITDA Margin % | 8.31 | |||||
FCF Margin % | 11.28 | |||||
OCF Margin % | 14.95 | |||||
ROE % | -1.88 | |||||
ROA % | -1.21 | |||||
ROIC % | 6.64 | |||||
3-Year ROIIC % | -630.67 | |||||
ROC (Joel Greenblatt) % | -0.25 | |||||
ROCE % | -0.23 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | 59.28 | |||||
PS Ratio | 3.25 | |||||
PB Ratio | 3.33 | |||||
Price-to-Tangible-Book | 3.34 | |||||
Price-to-Free-Cash-Flow | 28.76 | |||||
Price-to-Operating-Cash-Flow | 21.71 | |||||
EV-to-EBIT | -1107.91 | |||||
EV-to-EBITDA | 41.41 | |||||
EV-to-Revenue | 3.44 | |||||
EV-to-FCF | 30.52 | |||||
Price-to-GF-Value | 1.56 | |||||
Price-to-Projected-FCF | 38.29 | |||||
Price-to-Median-PS-Value | 1.23 | |||||
Price-to-Graham-Number | 2.96 | |||||
| Price-to-Net-Current-Asset-Value | 24.93 | |||||
Earnings Yield (Greenblatt) % | -0.09 | |||||
FCF Yield % | 3.48 | |||||
Forward Rate of Return (Yacktman) % | 7.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ICCC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ImmuCell Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 29.934 | ||
| EPS (TTM) ($) | -0.06 | ||
| Beta | 0.8757 | ||
| 3-Year Sharpe Ratio | 0.64 | ||
| 3-Year Sortino Ratio | 1.19 | ||
| Volatility % | 54.51 | ||
| 14-Day RSI | 54.56 | ||
| 14-Day ATR ($) | 0.598361 | ||
| 20-Day SMA ($) | 10.274 | ||
| 12-1 Month Momentum % | 52.24 | ||
| 52-Week Range ($) | 4.52 - 12.1 | ||
| Shares Outstanding (Mil) | 9.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ImmuCell Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ImmuCell Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 09:00 | In 121 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 120 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 09:00 | In 30 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 29 days | ||
| General meeting for 2026 | 2026-06-11 09:30 | 9.67 (-1.28%) | ||
| First quarter earnings conference call for 2026 | 2026-05-15 09:00 | 8.26 (-2.82%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 8.36 (-3.02%) | ||
| Annual report for 2025 | 2026-03-30 | 6.52 (+0.77%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 09:00 | 6.46 (+2.38%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-04 | 6.40 (-1.54%) |
Show
Entries
ImmuCell Corp Frequently Asked Questions
What is ImmuCell Corp(ICCC)'s stock price today?
The current price of ICCC is $10.72. The 52 week high of ICCC is $12.10 and 52 week low is $4.52.
When is next earnings date of ImmuCell Corp(ICCC)?
The next earnings date of ImmuCell Corp(ICCC) is 2026-08-14.
Does ImmuCell Corp(ICCC) pay dividends? If so, how much?
ImmuCell Corp(ICCC) does not pay dividend.
Guru Commentaries on NAS:ICCC
No articles.
Press Release
Articles on ImmuCell Corp
Insider Buying: te Boekhorst Paul Francis Olivier Acquires Additional Shares of ImmuCell Corp (ICCC)
Jun 22, 2026
Headlines
See More- 1
Jul 09, 2026
ImmuCell reports preliminary Q2 sales increase of 11.5% to $7.2M
Seeking Alpha • 3:33pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers